(Q38168948)

30 August 2017

title

Anakinra for cryopyrin-associated periodic syndrome (English)

1 reference

cryopyrin-associated periodic syndrome

30 August 2017

main subject

0 references

1 reference

1

Isabelle Koné-Paut

1 reference

30 August 2017

Caroline Galeotti

2

1 reference

30 August 2017

publication date

21 November 2013

1 reference

Expert Review of Clinical Immunology

30 August 2017

published in

1 reference

30 August 2017

volume

10

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

7-18

1 reference

Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Muckle-Wells syndrome and male hypofertility: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Autoinflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Immunological and inflammatory functions of the interleukin-1 family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

The infevers autoinflammatory mutation online registry: update with new genes and functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Use of canakinumab in the cryopyrin-associated periodic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Natural history and outcome in systemic AA amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Detection of base substitution-type somatic mosaicism of the NLRP3 gene with >99.9% statistical confidence by massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.861325

10.1586/1744666X.2014.861325

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference